|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...8283848586878889909192...110111» |
- motolimod (VTX 2337) / BMS
Enrollment closed, Combination therapy: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Jul 17, 2013
P1, N=36, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting
- Enrollment change: Identification of Viable Human Embryos Using Three Different Methods (clinicaltrials.gov) - Jul 16, 2013
P=N/A, N=161, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting N=100 --> 161
- Trial completion: Identification of Viable Human Embryos Using Three Different Methods (clinicaltrials.gov) - Jul 16, 2013
P=N/A, N=161, Completed, Sponsor: University of Aarhus
N=100 --> 161 Recruiting --> Completed
- cisplatin / Generic mfg., pemetrexed / Generic mfg., paclitaxel / Generic mfg.
Enrollment change: Alimta (clinicaltrials.gov) - Jul 16, 2013
P1, N=15, Completed, Sponsor: University of Arizona
Recruiting --> Completed N=30 --> 15
- cisplatin / Generic mfg., pemetrexed / Generic mfg., paclitaxel / Generic mfg.
Trial completion: Alimta (clinicaltrials.gov) - Jul 16, 2013
P1, N=15, Completed, Sponsor: University of Arizona
N=30 --> 15 Active, not recruiting --> Completed
- |||| irosustat (BN 83495) / Ipsen
Trial completion, Metastases: The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Jul 15, 2013
P2, N=73, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- leuprolide acetate for depot suspension / Generic mfg., pioglitazone / Generic mfg.
Trial termination: Polycystic Ovary Syndrome (PCOS) and Sleep Apnea (clinicaltrials.gov) - Jul 15, 2013
P4, N=37, Terminated, Sponsor: University of Chicago
Active, not recruiting --> Completed Completed --> Terminated; Did not meet target patient accrual goals
- leuprolide acetate for depot suspension / Generic mfg., pioglitazone / Generic mfg.
Enrollment change: Polycystic Ovary Syndrome (PCOS) and Sleep Apnea (clinicaltrials.gov) - Jul 15, 2013
P4, N=37, Terminated, Sponsor: University of Chicago
Completed --> Terminated; Did not meet target patient accrual goals N=130 --> 37
- ||| Trial completion: Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease (clinicaltrials.gov) - Jul 15, 2013
P=N/A, N=47208, Completed, Sponsor: Hoffmann-La Roche
N=130 --> 37 Active, not recruiting --> Completed
- | EP-100 / Esperance Pharma
Enrollment closed: ESP2011-002: EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer (clinicaltrials.gov) - Jul 14, 2013
P2, N=48, Active, not recruiting, Sponsor: Esperance Pharmaceuticals Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: Pilot Study to Assess the Efficacy of Cognitive-behavioral Couple Therapy for Provoked Vestibulodynia (clinicaltrials.gov) - Jul 13, 2013
P=N/A, N=30, Active, not recruiting, Sponsor: Université de Montréal
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Enrollment change: A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale (clinicaltrials.gov) - Jul 11, 2013
P2, N=567, Completed, Sponsor: Duramed Research
Recruiting --> Active, not recruiting N=400 --> 567
- Clinical: MANI-PCOS: Mood and Nutrition Interventions in Polycystic Ovary Syndrome (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=50, Recruiting, Sponsor: University of Pennsylvania
- Victoza (liraglutide) / Novo Nordisk
New P4 trial: Polycystic Ovary Syndrome and Liraglutide (clinicaltrials.gov) - Jul 11, 2013
P4, N=32, Completed, Sponsor: University Medical Centre Ljubljana
- ||| Trial completion: Comparison of Aneuploidy Risk Evaluations (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=3000, Completed, Sponsor: Verinata Health, Inc.
N=400 --> 567 Recruiting --> Completed
- Trial termination: GoldenCareTM for the Treatment of Bacterial Vaginosis (clinicaltrials.gov) - Jul 10, 2013
P1/2, N=8, Terminated, Sponsor: CDA Research Group, Inc.
Recruiting --> Completed Recruiting --> Terminated; Company decided to stop study for reasons other than safety
- Enrollment change: GoldenCareTM for the Treatment of Bacterial Vaginosis (clinicaltrials.gov) - Jul 10, 2013
P1/2, N=8, Terminated, Sponsor: CDA Research Group, Inc.
Recruiting --> Terminated; Company decided to stop study for reasons other than safety N=60 --> 8
- Trial completion: Herbal Tonic Fertile Supplement(ZO2C5) (clinicaltrials.gov) - Jul 10, 2013
P3, N=1, Completed, Sponsor: Arash Khaki
N=60 --> 8 Not yet recruiting --> Completed
- Norditropin (somatropin) / Novo Nordisk, Cetrotide (cetrorelix) / EMD Serono
Enrollment open: IVF/ICSI Protocols in Poor Responders With Growth Hormone (clinicaltrials.gov) - Jul 10, 2013
P4, N=287, Recruiting, Sponsor: Woman's Health University Hospital, Egypt
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Development & Validation of Utilities for Health States Relevant to Cervical Cancer Patients (clinicaltrials.gov) - Jul 10, 2013
P=N/A, N=60, Completed, Sponsor: Duke University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P3 trial: Herbal Tonic Fertile Supplement(ZO2C5) (clinicaltrials.gov) - Jul 9, 2013
P3, N=1, Completed, Sponsor: Arash Khaki
- | Norditropin (somatropin) / Novo Nordisk, Cetrotide (cetrorelix) / EMD Serono
New P4 trial: IVF/ICSI Protocols in Poor Responders With Growth Hormone (clinicaltrials.gov) - Jul 9, 2013
P4, N=287, Recruiting, Sponsor: Woman's Health University Hospital, Egypt
- zoledronic acid / Generic mfg.
Trial termination: Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer (clinicaltrials.gov) - Jul 8, 2013
P2, N=3, Terminated, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Withdrawn --> Terminated; Lack of enrollment
- zoledronic acid / Generic mfg.
Enrollment change: Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer (clinicaltrials.gov) - Jul 8, 2013
P2, N=3, Terminated, Sponsor: Washington University School of Medicine
Withdrawn --> Terminated; Lack of enrollment N=70 --> 3
- metformin / Generic mfg.
Enrollment closed: Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=70 --> 3 Recruiting --> Active, not recruiting
- || Enrollment change: FAST-EU: Fibroid Ablation Study (clinicaltrials.gov) - Jul 5, 2013
P=N/A, N=100, Active, not recruiting, Sponsor: Gynesonics
Recruiting --> Active, not recruiting N=48 --> 100
- Enrollment closed: FAST-L: Fibroid Ablation Study - Large Fibroids (clinicaltrials.gov) - Jul 5, 2013
P=N/A, N=48, Active, not recruiting, Sponsor: Gynesonics
N=48 --> 100 Recruiting --> Active, not recruiting
- || Enrollment closed: FAST-EU: Fibroid Ablation Study (clinicaltrials.gov) - Jul 5, 2013
P=N/A, N=100, Active, not recruiting, Sponsor: Gynesonics
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || New P3 trial: Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy (clinicaltrials.gov) - Jul 4, 2013
P3, N=80, Recruiting, Sponsor: CHA University
- Biomarker, Enrollment open: MR Metabolic Biomarkers for Cervical Cancer (clinicaltrials.gov) - Jul 4, 2013
P=N/A, N=120, Recruiting, Sponsor: Chang Gung Memorial Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Menopur (menotropin) / Ferring
Trial completion, Preclinical: PREDICT: Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF) (clinicaltrials.gov) - Jul 3, 2013
P4, N=124, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial withdrawal: FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=0, Withdrawn, Sponsor: Emory University
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=0, Withdrawn, Sponsor: Emory University
Not yet recruiting --> Withdrawn N=66 --> 0
- |||| pavinetant (AZD4901) / AstraZeneca, Millendo Therap
Enrollment open: A Study of AZD4901 in Females With Polycystic Ovary Syndrome (clinicaltrials.gov) - Jul 2, 2013
P2a, N=56, Recruiting, Sponsor: AstraZeneca
N=66 --> 0 Not yet recruiting --> Recruiting
- cisplatin / Generic mfg.
Trial completion, Metastases: Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix (clinicaltrials.gov) - Jul 2, 2013
P2, N=0, Completed, Sponsor: Mount Sinai School of Medicine
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | otesaconazole (VT-1161) / Mycovia Pharma
New P2 trial: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Jul 1, 2013
P2, N=48, Active, not recruiting, Sponsor: Viamet Pharmaceuticals, Inc.
- ||||||| Cetrotide (cetrorelix) / EMD Serono
Trial completion: ATTAC-PCO: Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) (clinicaltrials.gov) - Jul 1, 2013
P3, N=136, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| PF-06263507 / Pfizer
New P1 trial, Metastases: A Study Of PF-06263507 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 1, 2013
P1, N=75, Recruiting, Sponsor: Pfizer
- SG 2000 / AstraZeneca
Trial termination: SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin (clinicaltrials.gov) - Jun 30, 2013
P2, N=50, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Terminated; Slow accrual was the reason for study termination.
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Enrollment open, PARP Biomarker, Metastases: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 30, 2013
P1, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated; Slow accrual was the reason for study termination. Suspended --> Recruiting
- clomifene citrate / Generic mfg.
Trial completion: Luteal Support and Intrauterine Insemination (IUI) With Clomiphene Citrate (clinicaltrials.gov) - Jun 30, 2013
P=N/A, N=300, Completed, Sponsor: Universitair Ziekenhuis Brussel
Suspended --> Recruiting Active, not recruiting --> Completed
- aminoflavone Prodrug (AFP-464) / Kirax
Trial completion, Surgery, Metastases: AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 30, 2013
P1, N=68, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion, Combination therapy, Metastases: 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (clinicaltrials.gov) - Jun 30, 2013
P1, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cetrotide (cetrorelix) / EMD Serono
Trial initiation date: GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome (clinicaltrials.gov) - Jun 27, 2013
P3, N=100, Completed, Sponsor: Instituto Valenciano de Infertilidad, Spain
Active, not recruiting --> Completed Initiation date: Dec 2010 --> Apr 2012
- | Cetrotide (cetrorelix) / EMD Serono
Enrollment change: GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome (clinicaltrials.gov) - Jun 27, 2013
P3, N=100, Completed, Sponsor: Instituto Valenciano de Infertilidad, Spain
Initiation date: Dec 2010 --> Apr 2012 N=62 --> 100
- | Cetrotide (cetrorelix) / EMD Serono
Trial completion: GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome (clinicaltrials.gov) - Jun 27, 2013
P3, N=100, Completed, Sponsor: Instituto Valenciano de Infertilidad, Spain
N=62 --> 100 Recruiting --> Completed
- Enrollment closed, Oncolytic virus: Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 27, 2013
P1, N=46, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Alpha Lipoic Acid and Polycystic Ovary Syndrome (clinicaltrials.gov) - Jun 27, 2013
P1, N=22, Completed, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Biomarker, Enrollment open: Individualization of Ovarian Stimulation Using AMH Maximizes the Benefits and Minimizes Complications and Risks (clinicaltrials.gov) - Jun 25, 2013
P=N/A, N=250, Recruiting, Sponsor: ANDROFERT - Clinica de Andrologia e Reproducao Humana
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Clinical: Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma (clinicaltrials.gov) - Jun 25, 2013
P=N/A, N=15, Not yet recruiting, Sponsor: Washington University School of Medicine